Cytoplasmic overexpression of HER2: A key factor in colorectal cancer

Clinical Medicine Insights: Oncology

Volumn 7, Issue , 2012, Pages 41-51

  Blok, Erik J ^a   Kuppen, Peter J K ^a   van Leeuwen, Jeroen E M ^b   Sier, Cornelis F M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

Biomarker; Colorectal cancer; Cytoplasmic; ErbB2; HER2; Her2 neu; Herceptin; Immunohistochemistry; Membranous; Survival; Tissue microarray; Trastuzumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TATA BINDING PROTEIN;

CANCER PROGNOSIS; COLON CARCINOGENESIS; COLORECTAL CANCER; CYTOPLASM; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; NORTHERN BLOTTING; ONCOGENE NEU; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SCORING SYSTEM; SOUTHERN BLOTTING; UPREGULATION;

EID: 84874430114     PISSN: 11795549     EISSN: None     Source Type: Journal    
DOI: 10.4137/CMO.S10811     Document Type: Review

References (58)

1. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D. GLOBOCAN 2008 v1.2, Cancer incidence and mortality worldwide. Available at: http://globocan.iarc.fr. Accessed Jun 12, 2012.
2. SJ. The multidisciplinary management of gastrointestinal cancer. colorectal cancer screening. Best Pract Res Clin Gastroenterol. 2007; 2(6)1:1031-48.
3. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004; 350(23):2343-51.
4. Gutierrez C, Schiff R. HER2: Biology, detection, and clinical implications. Arch Pathol Lab Med. 2011;135(1):55-62.
5. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905): 707-12.
6. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177-82.
7. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-92.
8. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2006;369(9555):29-36.
9. Liu YH, Xu FP, Rao JY, et al. Justification of the change from 10% to 30% for the immunohistochemical her2 scoring criterion in breast cancer. Am J Clin Pathol. 2009;132(1):74-9.
10. Rhodes A, Jasani B, Anderson E, Dodson AR, Balaton AJ. Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am J Clin Pathol. 2002;118(3):408-17.
11. Seidman AD, Fornier MN, Esteva FJ, et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol. 2001; 19(20):2587-95.
12. Gouvea AP, Milanezi F, Olson SJ, Leitao D, Schmitt FC, Gobbi H. Selecting antibodies to detect HER2 overexpression by immunohistochemistry in invasive mammary carcinomas. Appl Immunohistochem Mol Morphol. 2006;14(1):103-8.
13. Press MF, Sauter G, Bernstein L, et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res. 2005;11(18):6598-607.
14. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 1928;376(9742):687-97.
15. Ross JS. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest. 2001;19(5):554-68.
16. Kay EW, Mulcahy H, Walsh CB, et al. Cytoplasmic c-erbB-2 protein expression correlates with survival in Dukes' B colorectal carcinoma. Histopathology. 1994;25(5):455-61.
17. Lazaris AC, Theodoropoulos GE, Anastassopoulos P, et al. Prognostic significance of p53 and c-erbB-2 immunohistochemical evaluation in colorectal adenocarcinoma. Histol Histopathol. 1995;10(3):661-8.
18. Osako T, Miyahara M, Uchino S, Inomata M, Kitano S, Kobayashi M. Immunohistochemical study of c-erbB-2 protein in colorectal cancer and the correlation with patient survival. Oncology. 1998;55(6):548-55.
19. Berney CR, Fisher RJ, Yang J, Russell PJ, Crowe PJ. Protein markers in colorectal cancer: predictors of liver metastasis. Ann Surg. 1999;230(2): 179-84.
20. Kluftinger AM, Robinson BW, Quenville NF, Finley RJ, Davis NL. Correlation of epidermal growth factor receptor and c-erbB2 oncogene product to known prognostic indicators of colorectal cancer. Surg Oncol. 1992;1(1):97-105.
21. Sun XF, Carstensen JM, Stål O, Zhang H, Nordenskjöld B. c-erbB-2 oncoprotein in relation to DNA ploidy and prognosis in colorectal adenocarcinoma. APMIS. 1995;103(4):309-15.
22. Gill MK, Manjari M, Jain K, et al. Expression of Her-2/neu in colon carcinoma and its correlation with the histological grades and the lymph nodes status. JCDR. 2011;5:1564-8.
23. Half E, Broaddus R, Danenberg KD, Danenberg PV, Ayers GD, Sinicrope FA. HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. Int J Cancer. 2004;108:540-8.
24. Kavanagh D, Chambers G, O'Grady L, et al. Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? BMC Cancer. 2009;9:1.
25. Kim JY, Lim SJ, Park K. Cyclooxygenase-2 and c-erbB-2 expression in colorectal carcinoma assessed using tissue microarrays. Appl Immunohistochem Mol Morphol. 2004;12(1):67-70.
26. Kountourakis P, Pavlakis K, Psyrri A, et al. Clinicopathologic significance of EGFR and Her-2/neu in colorectal adenocarcinomas. Cancer J. 2006;12(3):229-36.
27. Li Q, Wang D, Li J, Chen P. Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas. BMC Cancer. 2011;11:277.
28. Nathanson DR, Culliford AT, Shia J, et al. HER 2/neu expression and gene amplification in colon cancer. Int J Cancer. 2003;105(6):796-802.
29. Ooi A, Takehana T, Li X, et al. Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study. Mod Pathol. 2004;17(8):895-904.
30. Schuell B, Gruenberger T, Scheithauer W, Zielinski CH, Wrba F. HER 2/neu protein expression in colorectal cancer. BMC Cancer. 2006;6:123.
31. Ochs AM, Wong L, Kakani V, et al. Expression of vascular endothelial growth factor and HER2/neu in stage II colon cancer and correlation with survival. Clin Colorectal Cancer. 2004;4(4):262-7.
32. Demirbas S, Sucullu I, Yildirim S, Celenk T. Influence of the c-erb B-2, nm23, bcl-2 and p53 protein markers on colorectal cancer. Turk J Gastroenterol. 2006;17(1):13-9.
33. Jesus EC, Matos D, Artigiani R, Waitzberg AF, Goldenberg A, Saad SS. Assessment of staging, prognosis and mortality of colorectal cancer by tumor markers: receptor erbB-2 and cadherins. Acta Cir Bras. 2005;20(6): 422-7.
34. Knösel T, Yu Y, Stein U, et al. Overexpression of c-erbB-2 protein correlates with chromosomal gain at the c-erbB-2 locus and patient survival in advanced colorectal carcinomas. Clin Exp Metastasis. 2002;19(5):401-7.
35. Kruszewski WJ, Rzepko R, Ciesielski M, et al. Expression of HER2 in colorectal cancer does not correlate with prognosis. Dis Markers. 2010; 29(5):207-12.
36. Park DI, Kang MS, Oh SJ, et al. HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. Int J Colorectal Dis. 2007;22(5):491-7.
37. Porcelli B, Frosi B, Terzuoli L, et al. Expression of P185 and P53 in benign and malignant colorectal lesions. Histochem J. 2001;33(1):51-7.
38. Uner A, Ebinc FA, Akyurek N, Unsal D, Mentes BB, Dursun A. Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma. Exp Oncol. 2005;27(3):225-8.
39. Mirlacher M, Kasper M, Storz M, et al. Influence of slide aging on results of translational research studies using immunohistochemistry. Mod Pathol. 2004;17(11):1414-20.
40. van Nes J, de Kruijf E, Faratian D, et al. COX2 expression in prognosis and in prediction to endocrine therapy in early breast cancer patients. Breast Cancer Res Treat. 2011;125(3):671-85.
41. Arnaout AH, Dawson PM, Soomro S, et al. HER2 (c-erbB-2) oncoprotein expression in colorectal adenocarcinoma: an immunohistological study using three different antibodies. J Clin Pathol. 1992;45(8):726-7.
42. McCann A, Dervan PA, Johnston PA, Gullick WJ, Carney DN. c-erbB-2 oncoprotein expression in primary human tumors. Cancer. 1990;65(1):88-92.
43. Dursun A, Poyraz A, Suer O, Sezer C, Akyol G. Expression of Bcl-2 and c-ErbB-2 in colorectal neoplasia. Pathol Oncol Res. 2001;7(1):24-7.
44. McKay JA, Loane JF, Ross VG, et al. c-erbB-2 is not a major factor in the development of colorectal cancer. Br J Cancer. 2002;86(4):568-73.
45. Kapitanovic S, Radosevic S, Kapitanovic M, et al. The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterology. 1997;112(4):1103-13.
46. Maurer CA, Friess H, Kretschmann B, et al. Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum Pathol. 1998;29(8):771-7.
47. Schrohl AS, Pedersen HC, Jensen SS, Nielsen SL, Brünner N. Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies. Histopathology. 2011;59(5): 975-83.
48. Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 1994;54(10): 2771-7.
49. Walker RA, Bartlett JMS, Dowsett M, et al. HER2 testing in the UK: further update to recommendations. J Clin Pathol. 2008;61(7):818-24.
50. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733-43.
51. Taylor SL, Platt-Higgins A, Rudland PS, Winstanley JH, Barraclough R. Cytoplasmic staining of c-erbB-2 is not associated with the presence of detectable c-erbB-2 mRNA in breast cancer specimens. Int J Cancer. 1998;76(4): 459-63.
52. Têtu B, Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer. 1994;73(9):2359-65.
53. de Potter CR, van Daele S, van de Vijver MJ, et al. The expression of the neu oncogene product in breast lesions and in normal fetal and adult human tissues. Histopathology. 1989;15(4):351-62.
54. Pavlakis K, Kountourakis P, Stathopoulos E, et al. Her-2 protein expression, cellular localization, and gene amplification in colorectal carcinoma. Appl Immunohistochem Mol Morphol. 2007;15(4):441-5.
55. Kameda T, Yasui W, Yoshida K, et al. Expression of ERBB2 in human gastric carcinomas: relationship between p185erbb2 expression and the gene amplification. Cancer Res. 1990;50(24):8002-9.
56. Scriven P, Coulson S, Haines R, Balasubramanian S, Cross S, Wyld L. Activation and clinical significance of the unfolded protein response in breast cancer. Br J Cancer. 2009;101(10):1692-8.
57. Ramanathan RK, Hwang JJ, Zamboni WC, et al. Low overexpression of HER-2/Neu in advanced colorectal cancer limits the usefulness of trastuzumab (herceptin) and irinotecan as therapy. A Phase II Trial. Cancer Invest. 2004;22(6):858-65.
58. Meijer IMJ, van Leeuwen JEM. ERBB2 is a target for USP8-mediated deubiquitination. Cell Signal. 2011;23(2):458-67.